Context: Scientists from Department of Atomic Energy and IDRS Labs, Bengaluru have together developed Aktocyte tablets with the primary aim of minimising the side effects of radiotherapy. The tablet is a breakthrough towards enhancing the quality of life for cancer patients undergoing radiotherapy.
About Aktocyte
- Aktocyte tablets have shown remarkable results, particularly in pelvic cancer patients suffering from radiotherapy induced Cystisis (Blood in urine).
- Pateints treated with Aktocyte have demonstrated an extraordinary recovery, eliminating the need for surgical removal of urinary bladder.
- The tablets designed as an adjuvant to cancer radiotherapy, regenerative nutraceutical, immuno-modulator and antioxidant marks a significant advancement in cancer care.
- Aktocyte has received approval from FSSAI, operating under MoHFW of Government of India. This regulatory clearance emphasises the safety and compliance of Aktocyte tablets, providing assurance to both healthcare professionals and patients about its efficacy and quality.